Antiviral peptides against dengue virus
Dengue virus (DENV) poses a continuous threat to the public health of the global community with over 390 million infections and 25,000 deaths annually. The efficacy of the only licensed dengue vaccine, Dengvaxia, against all four DENV serotypes is less than desirable in real-world setting. In additi...
Saved in:
Main Authors: | Lee, Michelle Felicia *, Anasir, Mohd Ishtiaq, Poh, Chit Laa * |
---|---|
Format: | Book Section |
Published: |
Academic Press
2022
|
Subjects: | |
Online Access: | http://eprints.sunway.edu.my/2160/ https://www.sciencedirect.com/science/article/pii/B9780323918145000106?via%3Dihub |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Development of novel antiviral peptides against dengue serotypes 1-4
by: Lee, Michelle Felicia, et al.
Published: (2023) -
Molecular Mechanisms of Antiviral Agents against Dengue Virus
by: Lee, Michelle Felicia, et al.
Published: (2023) -
Serum Stabilities and Antiviral Activities of Chemically Modified Peptides Against Dengue Serotypes 1–4
by: Lee, Michelle Felicia *, et al.
Published: (2024) -
Innate and adaptive immune evasion by dengue virus
by: Lee, Michelle Felicia *, et al.
Published: (2022) -
Antiviral peptides against SARS-CoV-2: therapeutic targets, mechanistic antiviral activity, and efficient delivery
by: Raahilah, Zahir Essa, et al.
Published: (2022)